Incyte (INCY) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Incyte Corp. Stock Rises Tuesday, Still Underperforms Market
MarketWatchDec 24 17:22 ET
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Seeking AlphaDec 22 10:12 ET
Wells Fargo Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $70
Moomoo NewsDec 20 13:31 ET · Ratings
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Kevin TraversDec 20 10:29 ET
Incyte Price Target Raised to $70 From $68 at Wells Fargo
Yahoo FinanceDec 20 07:20 ET
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
BenzingaDec 19 16:01 ET

Comments

韭菜变主力

Nov 19 12:59

$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.

3

The Thinker

Oct 29 19:14

Tech Stocks Surge While Dow Falters as U.S. Markets Prepare for Key Data

Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...

+2

2

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

8

Trytosaveabit

Aug 14 16:41

News

$Syndax Pharmaceuticals (SNDX.US)$ $Incyte (INCY.US)$ Reuters
5 mins ago
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)

2

INCY Incyte

Trade Overview

Capital Trend

News

Comments